PCI Biotech announced that results from preclinical studies on tuberculosis performed in collaboration with The University of Zurich and ETH Zurich are accepted for publication in Frontiers in Immunology, a high impact immunology journal. The article title is 'Photochemically-mediated inflammation and cross-presentation of Mycobacterium bovis BCG proteins stimulates strong CD4 and CD8 T-cell responses in mice'.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.6 NOK | -2.91% | +0.13% | -23.63% |
1st Jan change | Capi. | |
---|---|---|
-23.63% | 5.51M | |
+3.91% | 109B | |
+10.87% | 105B | |
+1.28% | 22.25B | |
-13.14% | 22.09B | |
-7.05% | 18.68B | |
-38.36% | 17.58B | |
-10.66% | 16.85B | |
+3.75% | 13.76B | |
+36.70% | 12.46B |
- Stock Market
- Equities
- PCIB Stock
- News PCI Biotech Holding ASA
- PCI Biotech Announces Publication of Preclinical Tuberculosis Results